Moderna (NASDAQ:MRNA) Sets New 12-Month Low After Analyst Downgrade

Moderna, Inc. (NASDAQ:MRNA)’s share price reached a new 52-week low during mid-day trading on Monday after Barclays lowered their price target on the stock from $125.00 to $111.00. Barclays currently has an overweight rating on the stock. Moderna traded as low as $45.44 and last traded at $45.44, with a volume of 945656 shares changing hands. The stock had previously closed at $46.83.

Several other equities research analysts have also recently weighed in on the stock. Hsbc Global Res raised shares of Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 28th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research report on Thursday, September 19th. JPMorgan Chase & Co. lowered their price target on shares of Moderna from $70.00 to $59.00 and set an “underweight” rating for the company in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and reduced their price objective for the stock from $85.00 to $80.00 in a research note on Wednesday, August 7th. Finally, Piper Sandler reduced their price objective on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, September 13th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $93.18.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO James M. Mock sold 715 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,930 shares of company stock worth $217,170. 15.70% of the stock is owned by corporate insiders.

Institutional Trading of Moderna

Hedge funds have recently added to or reduced their stakes in the company. Intrinsic Value Partners LLC boosted its holdings in Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock worth $3,435,000 after buying an additional 24,505 shares in the last quarter. Vontobel Holding Ltd. boosted its holdings in Moderna by 148.2% during the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock worth $7,758,000 after buying an additional 69,313 shares in the last quarter. Profund Advisors LLC boosted its holdings in Moderna by 20.9% during the second quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock worth $6,676,000 after buying an additional 9,719 shares in the last quarter. Tobam boosted its holdings in Moderna by 121.6% during the third quarter. Tobam now owns 27,794 shares of the company’s stock worth $1,857,000 after buying an additional 15,249 shares in the last quarter. Finally, Privium Fund Management B.V. boosted its holdings in Moderna by 74.0% during the third quarter. Privium Fund Management B.V. now owns 40,482 shares of the company’s stock worth $2,705,000 after buying an additional 17,221 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

The stock’s fifty day moving average is $61.85 and its 200-day moving average is $99.09. The stock has a market capitalization of $16.43 billion, a PE ratio of -7.28 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 3.92.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company’s revenue was up 3.8% compared to the same quarter last year. During the same period last year, the firm posted ($1.39) earnings per share. As a group, equities analysts predict that Moderna, Inc. will post -9.89 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.